Candidiasis News and Research

RSS

Candiadiasis, or Thrush, is a fungal infection caused by a group of yeast. There is a score of Candida species, the commonest of which is Candida albicans. They normally inhabit the surfaces and mucus linings of the human body. This includes mouth, vaginal cavity gastrointestinal tract etc.

Study develops simple, new treatment to fight Candida Albicans fungus

A study led by the UPV/EHU has developed an innovative, simple treatment based uterine stem cells to combat the Candida Albicans fungus, responsible for vaginal candidiasis disease.

5 Feb 2019

SCYNEXIS announces positive results from first interim efficacy analysis of FURI study

SCYNEXIS, Inc., a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from the first interim efficacy analysis of the ongoing FURI study.

1 Feb 2019

FDA approves first generic version of commonly prescribed asthma inhaler

The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.

30 Jan 2019

Cloned antibodies show potential to treat, diagnose life-threatening fungal infections

Despite public health efforts, many people who get fungal infections in their blood streams die, even if they can be identified and treated with antifungal drugs. These therapies are often ineffective on their own and increasingly the infections are becoming resistant to treatment with some of the front line antifungal drugs.

11 Dec 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.

27 Sep 2018

Mycovia initiates two Phase 3 clinical trials to evaluate VT-1161 in patients with RVVC

Mycovia Pharmaceuticals, making its official debut as a company developing therapies in women's health and dermatology, today announced the initiation of two Phase 3 clinical trials called VIOLET to evaluate the safety and efficacy of its lead candidate, VT-1161, in patients with recurrent vulvovaginal candidiasis

6 Sep 2018

Dectin-1 pathway could be important new target for treatment of candidiasis, study shows

Candida albicans infection (candidiasis) can cause skin, genital, or oral pain. Many studies have attempted to understand the source of pain in candidiasis; none have provided a clear explanation, until now.

29 Aug 2018

Scientists sequence and analyze genomes of Candida albicans

Candida albicans is one of the most formidable fungal species, causing infection in humans. Investigating the structure and reproduction methods of pathogenic populations can help us to understand how they emerge and spread.

10 Jul 2018

NovaDigm Therapeutics initiates NDV-3A Phase 2a study for reduction of S. aureus in military trainees

NovaDigm Therapeutics, a company developing innovative immuno-therapeutics and preventative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 2a study evaluating NDV-3A for the reduction of Staphylococcus aureus (S. aureus) colonization in a high-risk population of military trainees.

19 Apr 2018

Could a rare, deadly ‘superbug’ fungus be gaining a foothold?

The number of U.S. patients infected with a rare but dangerous fungal "superbug" called Candida auris has climbed quickly to 200 as of Dec. 31, according to the latest figures from the federal Centers for Disease Control and Prevention.

12 Feb 2018

New genetic analysis of candidiasis reveals surprising fungal sex secrets

Working together with researchers in the Université Paris-Sud in France and University Medical Centre Göttingen in Germany, ICREA Research Professor Toni Gabaldón and his team at the Centre for Genomic Regulation in Barcelona read the genetic code of 33 separate strains of the yeast Candida glabrata, the second most common cause of candidiasis.

15 Dec 2017

New testing regime could speed up diagnosis and treatment of SCID in infants

Babies born with Severe Combined Immune Deficiency (SCID) syndrome are defenceless against bacterial and viral infections that would be virtually harmless to most healthy people. If untreated, SCID is often fatal within a baby's first year of life.

13 Sep 2017

Multi-drug resistant fungi found in UK hospitals - alarms health officials

Latest reports have confirmed that over 200 patients in England have been infected with a drug-resistant fungus called Candida auris that was first detected in Japan. High alerts have been put in place to look out for further infections and prevent spread.

15 Aug 2017

Cocktail of drugs for HIV patients with advanced immunosuppression reduced deaths by 27%, study shows

A study published in the New England Journal of Medicine on 20th July 2017 suggests that a cocktail of drugs, if provided at the beginning of the HIV therapy, can save over 10,000 lives per year. HIV, which is often diagnosed late, leaves people vulnerable to other diseases by ravaging the immune system.

25 Jul 2017

Scientists discover new approach for antifungal drug treatments

Each year, invasive fungal infections sicken an estimated 2 million people worldwide and kill nearly 800,000 - but a team of international scientists have discovered a new approach for antifungal drug treatments.

15 Jun 2017

Recent estimates reveal burden of serious fungal diseases in 14 different countries

Estimates never before attempted, show the number of people affected by serious fungal diseases in 14 of the worst affected countries across the globe have just been published.

22 Feb 2017

Better fungal disease diagnostics could be critical to fight against antimicrobial resistance

Poor diagnosis worldwide of fungal disease causes doctors to overprescribe antibiotics, increasing harmful resistance to antimicrobial drugs, according to a paper published today in Emerging Infectious Diseases.

17 Jan 2017

TUM researchers discover vital mechanism in the body's defenses against fungal infections

Fungal infections are a serious health risk. They can be harmful especially to patients whose immune system is compromised through illness or chemotherapy.

19 Dec 2016

Allergan launches first and only oral contraceptive in softgel capsule for prevention of pregnancy

Allergan plc, a leading global pharmaceutical company, today announced the availability of TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1mg/20mcg, the first and only oral contraceptive in a softgel capsule for the prevention of pregnancy

10 Nov 2016